Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest announcement is out from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( (HK:1276) ).
Jiangsu Hengrui Pharmaceuticals Co., Ltd. announced that all resolutions proposed at its 2025 first extraordinary shareholders’ meeting were approved. The meeting saw participation from a significant number of shareholders and proxies, with a total of 3,068,160,282 shares carrying voting rights. Certain shareholders abstained from voting on resolutions related to the A Share Employee Stock Ownership Scheme. The approval of these resolutions is likely to impact the company’s operational strategies and stakeholder interests.
The most recent analyst rating on (HK:1276) stock is a Buy with a HK$94.54 price target. To see the full list of analyst forecasts on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H stock, see the HK:1276 Stock Forecast page.
More about Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H
Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a pharmaceutical company based in China, known for its development and production of a wide range of pharmaceutical products. The company is focused on innovation and has a significant presence in the pharmaceutical industry.
Average Trading Volume: 5,367,623
Current Market Cap: HK$500.1B
Learn more about 1276 stock on TipRanks’ Stock Analysis page.